Search

Home > GRACEcast Lung Cancer Video > ASCO 2012 LC Highlights: Dr. Joel Neal on the LUX-Lung 3 Trial of Afatinib vs. Chemo for EGFR Mutation-Positive Advanced NSCLC (video)
Podcast: GRACEcast Lung Cancer Video
Episode:

ASCO 2012 LC Highlights: Dr. Joel Neal on the LUX-Lung 3 Trial of Afatinib vs. Chemo for EGFR Mutation-Positive Advanced NSCLC (video)
Category: Science & Medicine
Duration: 00:05:13
Publish Date: 2012-09-12 07:29:52
Description:

Dr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.
Total Play: 0